Ginkgo Bioworks Holdings Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Vanguard S&P 500 Growth Index Fund ETF trades at $87.27 (market cap $27.10B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is far larger — about 35.5× Ginkgo Bioworks Holdings Inc's market cap, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Vanguard S&P 500 Growth Index Fund ETF for 54 Days on average.
| DNA | VOOG | |
|---|---|---|
Market Cap | $763.64M | $27.10B |
Volume | 3,204,177 | 1,178,312 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $87.81 |
52-Week Low | $5.48 | $65.32 |
Typical Hold Time | 7 Days | 54 Days |
Enterprise Value | $865.59M | — |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
VOOG trades at $87.69, down slightly by 0.14% on the day, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including an overbought RSI. The ETF, tracking the S&P 500 Growth Index, has delivered strong long-term returns, with recent news highlighting institutional buying and outperformance versus peers. Key support sits at $87, resistance at $88.
Outlook remains positive for long-term growth investors given VOOG's low expense ratio and historical outperformance, though near-term risks include tech sector concentration and market volatility. The ETF's focus on large-cap growth stocks positions it well for sustained appreciation, but investors should be cautious of valuation extremes in growth segments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →